Author:
Takahashi Tetta,Tomonobu Nahoko,Kinoshita Rie,Yamamoto Ken-ichi,Murata Hitoshi,Komalasari Ni Luh Gede Yoni,Chen Youyi,Jiang Fan,Gohara Yuma,Ochi Toshiki,Ruma I Made Winarsa,Sumardika I Wayan,Zhou Jin,Honjo Tomoko,Sakaguchi Yoshihiko,Yamauchi Akira,Kuribayashi Futoshi,Kondo Eisaku,Inoue Yusuke,Futami Junichiro,Toyooka Shinichi,Zamami Yoshito,Sakaguchi Masakiyo
Abstract
BackgroundOur earlier research revealed that the secreted lysyl oxidase-like 4 (LOXL4) that is highly elevated in triple-negative breast cancer (TNBC) acts as a catalyst to lock annexin A2 on the cell membrane surface, which accelerates invasive outgrowth of the cancer through the binding of integrin-β1 on the cell surface. However, whether this machinery is subject to the LOXL4-mediated intrusive regulation remains uncertain.MethodsCell invasion was assessed using a transwell-based assay, protein–protein interactions by an immunoprecipitation–Western blotting technique and immunocytochemistry, and plasmin activity in the cell membrane by gelatin zymography.ResultsWe revealed that cell surface annexin A2 acts as a receptor of plasminogen via interaction with S100A10, a key cell surface annexin A2-binding factor, and S100A11. We found that the cell surface annexin A2/S100A11 complex leads to mature active plasmin from bound plasminogen, which actively stimulates gelatin digestion, followed by increased invasion.ConclusionWe have refined our understanding of the role of LOXL4 in TNBC cell invasion: namely, LOXL4 mediates the upregulation of annexin A2 at the cell surface, the upregulated annexin 2 binds S100A11 and S100A10, and the resulting annexin A2/S100A11 complex acts as a receptor of plasminogen, readily converting it into active-form plasmin and thereby enhancing invasion.